Top Cystic Fibrosis Therapeutics Companies

Cystic Fibrosis Therapeutics Market size was valued at USD 7.42 Billion in 2024 and is poised to grow from USD 8.47 Billion in 2025 to USD 24.32 Billion by 2033, growing at a CAGR of 14.1% during the forecast period (2026–2033).

The cystic fibrosis therapeutics market competition consists of respiratory device manufacturers as well as standalone cystic fibrosis therapeutics producers. New technical advancements, such as the use of artificial intelligence, will generate growth prospects for new market entrants. For example, NuvoAir, a Swedish health care firm, created a digital platform that allows customers to perform at-home lung function tests. Companies are battling for market share, particularly in nations with advanced technology such as the United Kingdom, Germany, and the United States. Acquisitions and cooperation amongst market participants to strengthen their position have occurred. This is projected to increase market competition over the projection period. 'Vertex Pharmaceuticals (USA)', 'AbbVie (USA) ', 'Gilead Sciences (USA) ', 'Roche (Switzerland) ', 'Teva Pharmaceutical Industries (Israel) ', 'Mylan (now Viatris) (USA) ', 'Novartis AG (Switzerland) ', 'AstraZeneca (UK) ', 'Alaxia. ', 'Allergan (now part of AbbVie) (Ireland) ', 'Beyond Air Inc. (USA) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Merck & Co. Inc. (USA) ', 'Alcresta Therapeutics Inc. (USA) ', 'Chiesi (Italy) ', 'Nestlé HealthScience (Switzerland) ', 'Pharmaxis Ltd. (Australia) ', 'PTC Therapeutics, Inc. (USA) ', 'Insmed, Inc. (USA) ', 'Grifols S.A. (Spain)'

The primary driver of the cystic fibrosis therapeutics market is the increasing prevalence of cystic fibrosis, a genetic disorder that affects the respiratory, digestive, and reproductive systems. The disease is incurable and requires lifelong treatment, driving the demand for cystic fibrosis therapeutics.

Growing demand for personalized medicine: As the understanding of the genetic basis of cystic fibrosis improves, there is a growing demand for personalized medicine that targets the specific mutations responsible for the disease. This trend is expected to continue in the coming years, as newer therapies are developed that target specific mutations.

Asia Pacific had the largest cystic fibrosis market share in 2022 and is further expected to continue the same during the forecast period. The number of patients within the area is increasing and the urban lifestyle becomes more popular. This, together with increased healthcare spending, will most likely drive the APAC market. Furthermore, China's cystic fibrosis market had the highest market share, while India's cystic fibrosis market is the fastest expanding in the area.